Monthly pill trial aims to stop HIV before it starts
NCT ID NCT04644029
Summary
This study aimed to see if a new monthly oral pill (islatravir) could prevent HIV infection in women at high risk. It compared the monthly pill to a standard daily medication (FTC/TDF). The trial was stopped early for safety monitoring after lab tests showed potential effects on immune cells, but participants continued to be followed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROPHYLAXIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aurum Institute - Rustenburg ( Site 0022)
Rustenburg, North West, 0299, South Africa
-
Aurum Institute Klerksdorp CRS ( Site 0029)
Klerksdorp, North West, 2571, South Africa
-
Bronx Prevention Center ICAP ( Site 0062)
The Bronx, New York, 10451, United States
-
Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0020)
Johannesburg, Gauteng, 2092, South Africa
-
KC CARE Health Center-Clinical Trials ( Site 0059)
Kansas City, Missouri, 64111, United States
-
MU-JHU Care Limited-Clinic ( Site 0041)
Kampala, 10216, Uganda
-
Madibeng Centre for Research ( Site 0019)
Brits, North West, 0250, South Africa
-
Maternal Adolescent and Child Health Research (MatCH) ( Site 0025)
Durban, KwaZulu-Natal, 4001, South Africa
-
MedStar Health Research Institute (MedStar Physician Based R-MedStar Washington Hospital Center ( Si
Washington D.C., District of Columbia, 20010, United States
-
Orlando Immunology Center ( Site 0068)
Orlando, Florida, 32803, United States
-
Perinatal HIV Research Unit (PHRU)-HIV Prevention CRS ( Site 0023)
Johannesburg, Gauteng, 1864, South Africa
-
Ponce De Leon Center Grady Health ( Site 0066)
Atlanta, Georgia, 30308, United States
-
Prism Health North Texas, Oak Cliff Health Center ( Site 0070)
Dallas, Texas, 75208, United States
-
Prisma Health Richland Hospital-Clinical Research Unit ( Site 0069)
Columbia, South Carolina, 29203, United States
-
Qhakaza Mbokodo Research Clinic ( Site 0017)
Ladysmith, KwaZulu-Natal, 3370, South Africa
-
Rutgers New Jersey Medical School-Clinical Research Center ( Site 0071)
Newark, New Jersey, 07103, United States
-
SA Medical Research Council - Chatsworth Clinical Research Site ( Site 0030)
Chatsworth, KwaZulu-Natal, 4092, South Africa
-
Setshaba Research Centre ( Site 0016)
Pretoria, Gauteng, 0152, South Africa
-
The University of Mississippi Medical Center ( Site 0065)
Jackson, Mississippi, 39216, United States
-
The University of North Carolina at Chapel Hill-Medicine ( Site 0056)
Chapel Hill, North Carolina, 27599, United States
-
University of Alabama at Birmingham-UAB Sexual Health Research Clinic (SHRC) ( Site 0064)
Birmingham, Alabama, 35205, United States
-
University of Miami Miller School of Medicine-Infectious Disease ( Site 0076)
Miami, Florida, 33136, United States
-
West Virginia University-Department of Medicine ( Site 0061)
Morgantown, West Virginia, 26506, United States
-
Wits Reproductive Health and HIV Institute (WRHI)-Wits RHI Ward 21 Clinical Research site ( Site 002
Johannesburg, Gauteng, 2000, South Africa
Conditions
Explore the condition pages connected to this study.